RBC Capital analyst Brian Abrahams raised the firm’s price target on Biogen (BIIB) to $222 from $213 and keeps an Outperform rating on the shares after its Q1 earnings beat. With the company’s base business looking resilient enough and investors finally focusing on the emerging I&I – Immunology and Inflammation – pipeline, the stage is set for continued better sentiment and stock momentum, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Andrew Fein Reiterates Buy on Biogen, Lifts Price Target to $237 on De‑Risked BIIB080 Alzheimer’s Opportunity
- Biogen price target raised to $196 from $191 at Wedbush
- Biogen price target raised to $260 from $246 at Guggenheim
- Biogen Earns Buy Rating as Strong Q1 Results, Pipeline Progress and Apellis Deal Support $215 Price Target
- Biogen Earnings Call Highlights Turnaround Momentum